Yonjin Venture

TECLens, LLC is a development-stage company based in St. James, New York, focused on designing and manufacturing innovative medical contact lenses aimed at treating myopia and other vision issues. Founded in 2013, the company has developed the CXLens, a corneal crosslinking lens that offers a non-invasive, single treatment therapy requiring only a half-hour wear in a doctor's office. This technology features real-time ultrasound sensing and a high oxygen concentration environment for precise scleral positioning, enhancing targeting stability during treatment. TECLens aims to address a range of vision problems, including progressive myopia in children, presbyopia in adults, and conditions such as keratoconus. By providing a comfortable and effective alternative to traditional corrective lenses, TECLens seeks to reduce long-term eye health risks associated with extensive lens use.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Intressa Vascular is a medical technology company focused on developing advanced solutions for cardiovascular conditions, particularly aortic dissection. The company utilizes a proprietary braiding technology platform to create multilayer stents designed for endovascular treatment. This innovative approach enables physicians to effectively address the severe impacts of aortic dissections while minimizing the risk of ischemic complications. Through collaborative efforts and a commitment to high-quality product development, Intressa Vascular aims to enhance patient care and improve clinical outcomes in the treatment of cardiovascular diseases.

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing curative treatments for infectious diseases, with an initial focus on chronic Hepatitis B. This disease remains prevalent worldwide and has significant unmet medical needs. The company is pursuing two innovative approaches: fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. These therapies aim to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially achieving a functional cure for patients.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company founded in 2016 and located in Boston, Massachusetts. The company specializes in developing treatments for peripheral neuropathies, hemoglobinopathies, and specific oncology indications. Its innovative approach focuses on regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy's lead product, ricolinostat, serves as a selective HDAC6 inhibitor, which enables the treatment of conditions such as sickle cell disease and beta-thalassemia. Through its targeted therapeutic strategies, Regenacy aims to address significant unmet medical needs in various disease areas.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

Shenzhen Anteland Technology Co., Ltd, founded in 2015, specializes in the research and development, manufacturing, and sales of laser direct imaging equipment. The company has made significant investments in R&D, achieving advanced capabilities in micro and submicron lithography technology, and has established itself as a leader in the innovative DFAI technology. Anteland's laser exposure machines are versatile and cater to multiple industries, offering various exposure areas, light sources, and laser modules. Their products are utilized in sectors such as textile, decal, label printing, package printing, glass, semiconductor, and photovoltaic applications, providing customers with high precision and power solutions.

Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, that specializes in developing novel disease-modifying therapeutics aimed at addressing neurodegenerative diseases. Founded in 2019, the company focuses on restoring cellular balance disrupted by these conditions. Its therapeutic platform utilizes distinct molecular approaches to enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Libra Therapeutics targets multiple neurodegenerative disorders, including amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease, with the intention of offering effective treatments that mitigate the impact of these debilitating ailments.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates aimed at targeting and eliminating disease-causing proteins for the treatment of cancer, neurodegenerative diseases, and other conditions. The company's lead product candidate, CFT7455, is an orally bioavailable degrader targeting IKZF1/3, designed to treat multiple myeloma and various lymphomas. Additionally, C4 Therapeutics is advancing CFT8634, which targets BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors, as well as programs targeting BRAF V600E and RET for genetically defined resistant solid tumors. The company employs its proprietary Degronimid platform, which utilizes small molecule binders to flag harmful proteins for degradation by the cellular proteasome system, allowing for the potential treatment of previously undruggable targets. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics engages in strategic collaborations to enhance its research and development efforts.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company founded in 2016 and located in Boston, Massachusetts. The company specializes in developing treatments for peripheral neuropathies, hemoglobinopathies, and specific oncology indications. Its innovative approach focuses on regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy's lead product, ricolinostat, serves as a selective HDAC6 inhibitor, which enables the treatment of conditions such as sickle cell disease and beta-thalassemia. Through its targeted therapeutic strategies, Regenacy aims to address significant unmet medical needs in various disease areas.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Decipher Biosciences, Inc. is a genomic information company focused on the development and commercialization of clinical tests for urologic cancers. The company specializes in providing genomic tests such as Decipher Prostate Biopsy, which analyzes tumor tissue to tailor treatment based on the metastatic potential of prostate cancer. Additionally, Decipher Bladder offers genomic subtyping for muscle-invasive bladder cancer, assisting healthcare providers in determining which patients may benefit from neoadjuvant chemotherapy before radical cystectomy. Founded in 2008 and headquartered in San Diego, California, Decipher Biosciences also operates a research and development center in Vancouver, Canada. The company is actively expanding its GRID database, which consists of over 70,000 whole transcriptome profiles, and collaborates with pharmaceutical companies to identify biomarkers for new therapeutic responses.

Mesa Biotech, Inc. is a San Diego-based company that specializes in the design, development, manufacturing, and commercialization of molecular diagnostic tests aimed at infectious diseases. Founded in 2015, the company has developed innovative products such as the Accula Dock, which manages critical testing parameters, and various Accula test cassettes for detecting influenza and respiratory syncytial virus. Mesa Biotech's technology simplifies DNA and RNA molecular testing, merging the convenience of point-of-care testing with the sensitivity and specificity typically associated with laboratory-based diagnostics. This enables healthcare professionals to obtain actionable, laboratory-quality results directly at the point of care, enhancing the efficiency of disease management and treatment. The company also operates a satellite testing laboratory in Santa Fe, New Mexico.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.